Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution. (July 2017)

• Record Type: Journal Article
• Authors: Pessina, Federico; Navarria, Pierina; Cozzi, Luca; Tomatis, Stefano; Clerici, Elena; Ascolese, Anna Maria; Simonelli, Matteo; Perrino, Matteo; Riva, Marco; Rossi, Marco; Rudà, Roberta; Santoro, Armando; Bello, Lorenzo; Scorsetti, Marta
• Is Part Of: CNS oncology. Volume 6:Number 3(2017)
• Page Start: 211
• Page End: 219
• Publication Date: 2017-07
• Subjects: 2016 WHO classification -- anaplastic glioma -- chemotherapy -- multimodal approach -- radiotherapy -- surgery; Central nervous system -- Tumors -- Periodicals; 616.99481
• DOI: 10.2217/cns-2016-0043
• Languages: English
• ISSNs: 2045-0907

Abstract

Aim: To evaluate the outcome of newly diagnosed anaplastic glioma patients treated in our institution in relation to the 2016 WHO classification suggestions.Methods: This retrospective study included patients who underwent surgery plus adjuvant chemotherapy alone or concomitant and adjuvant chemoradiotherapy. Response was recorded using the Response Assessment in Neuro-Oncology criteria.Results: 123 patients were analyzed. The median progression-free survival time and the 2, 3 and 5 years progression-free survival rate were 27 months, 65.5, 21.2 and 21.2%; the 2, 3 and 5 years overall survival rate were 89.7, 83.0 and 58.4%. From the univariate/multivariate analysis, the factors conditioning survival were Karnofsky performance scale, extent of resection, IDH1 mutation status and presence of 1p/19q codeletion.Conclusion: The choice of adjuvant treatment have to consider molecular assessment and, in our experience, the extent of surgical resection.